tradingkey.logo

Nephros Inc

NEPH
5.200USD
-0.170-3.17%
Close 11/04, 16:00ETQuotes delayed by 15 min
55.12MMarket Cap
41.54P/E TTM

Nephros Inc

5.200
-0.170-3.17%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Nephros Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nephros Inc's Score

Industry at a Glance

Industry Ranking
73 / 160
Overall Ranking
207 / 4617
Industry
Professional & Commercial Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
5.500
Target Price
-3.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nephros Inc Highlights

StrengthsRisks
Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. It operates through the Water Filtration segment. In the medical markets, it sells water filtration products. In the commercial markets, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Its products are marketed primarily to the food service, hospitality, convenience store, and health care markets. These commercial products are also marketed into medical markets, as supplemental filtration to its medical filters. The Company’s filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 41.97% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.16M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 42.75, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.86M shares, increasing 3.13% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 323.44K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.63.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 8.39, which is higher than the Professional & Commercial Services industry's average of 7.31. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 4.42M, representing a year-over-year increase of 35.89%, while its net profit experienced a year-over-year increase of 182.01%.

Score

Industry at a Glance

Previous score
8.39
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

10.00

Operational Efficiency

8.81

Growth Potential

6.67

Shareholder Returns

6.46

Nephros Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 4.82, which is lower than the Professional & Commercial Services industry's average of 7.13. Its current P/E ratio is 42.75, which is 465.69% below the recent high of 241.82 and 158.31% above the recent low of -24.93.

Score

Industry at a Glance

Previous score
4.82
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 73/160
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.00, which is higher than the Professional & Commercial Services industry's average of 7.66. The average price target for Nephros Inc is 5.50, with a high of 6.00 and a low of 5.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Buy
Current Rating
5.500
Target Price
+2.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

25
Total
6
Median
8
Average
Company name
Ratings
Analysts
Nephros Inc
NEPH
2
Waste Connections Inc
WCN
26
Waste Management Inc
WM
26
Republic Services Inc
RSG
25
Veralto Corp
VLTO
20
GFL Environmental Inc
GFL
18
1
2
3
4
5

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 9.03, which is higher than the Professional & Commercial Services industry's average of 7.00. Sideways: Currently, the stock price is trading between the resistance level at 6.06 and the support level at 4.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.48
Change
-0.45

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.053
Neutral
RSI(14)
51.090
Neutral
STOCH(KDJ)(9,3,3)
53.663
Sell
ATR(14)
0.516
High Vlolatility
CCI(14)
17.985
Neutral
Williams %R
53.103
Neutral
TRIX(12,20)
0.615
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
5.466
Sell
MA10
5.366
Sell
MA20
5.307
Sell
MA50
4.724
Buy
MA100
4.271
Buy
MA200
3.122
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 3.00, which is lower than the Professional & Commercial Services industry's average of 6.91. The latest institutional shareholding proportion is 45.88%, representing a quarter-over-quarter decrease of 16.76%. The largest institutional shareholder is The Vanguard, holding a total of 323.44K shares, representing 3.05% of shares outstanding, with 59.28% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Wexford Capital LP
3.61M
+0.21%
Topline Capital Management, LLC
477.45K
+13.12%
Pessin (Sandra F)
369.71K
-13.91%
Pessin (Norman H)
344.13K
--
The Vanguard Group, Inc.
Star Investors
323.44K
+58.43%
Bard Associates Inc.
131.12K
-8.45%
Amron (Arthur H)
125.88K
--
Spandow (Oliver J)
114.84K
--
Pessin (Brian L.)
95.69K
-4.01%
Geode Capital Management, L.L.C.
93.19K
+3.21%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 2.17, which is lower than the Professional & Commercial Services industry's average of 5.57. The company's beta value is 1.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.17
Change
0
Beta vs S&P 500 index
1.47
VaR
+5.69%
240-Day Maximum Drawdown
+42.20%
240-Day Volatility
+100.93%

Return

Best Daily Return
60 days
+34.95%
120 days
+39.66%
5 years
+39.66%
Worst Daily Return
60 days
-9.15%
120 days
-14.20%
5 years
-40.59%
Sharpe Ratio
60 days
+2.88
120 days
+2.25
5 years
+0.24

Risk Assessment

Maximum Drawdown
240 days
+42.20%
3 years
+65.06%
5 years
+91.48%
Return-to-Drawdown Ratio
240 days
+5.79
3 years
+1.94
5 years
-0.07
Skewness
240 days
+2.40
3 years
+2.13
5 years
+1.21

Volatility

Realised Volatility
240 days
+100.93%
5 years
+88.44%
Standardised True Range
240 days
+4.71%
5 years
+3.90%
Downside Risk-Adjusted Return
120 days
+557.25%
240 days
+557.25%
Maximum Daily Upside Volatility
60 days
+81.81%
Maximum Daily Downside Volatility
60 days
+51.21%

Liquidity

Average Turnover Rate
60 days
+0.46%
120 days
+0.31%
5 years
--
Turnover Deviation
20 days
+163.41%
60 days
+137.38%
120 days
+58.63%

Peer Comparison

Professional & Commercial Services
Nephros Inc
Nephros Inc
NEPH
6.74 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
CoreCivic Inc
CoreCivic Inc
CXW
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
S&P Global Inc
S&P Global Inc
SPGI
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Huron Consulting Group Inc
Huron Consulting Group Inc
HURN
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
CRA International Inc
CRA International Inc
CRAI
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
CBIZ Inc
CBIZ Inc
CBZ
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI